

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



FUTURE WORLD HOLDINGS LIMITED

未 來 世 界 控 股 有 限 公 司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 572)

**SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO
THE ACQUISITIONS OF LISTED SECURITIES**

Reference is made to the announcement of the Company dated 28 October 2022 (the “**Announcement**”). Unless the context requires otherwise, capitalized terms used herein shall bear the same meanings as defined in the Announcement.

Central Wealth and its subsidiaries are principally engaged in securities and futures dealing business, trading of debts and equity investments, money lending business and Chinese medicine clinic business. It is noted that Central Wealth maintained certain revenues level in the past few years. The revenues of Central Wealth for the years ended 31 December 2018, 2019, 2020 and 2021 were approximately HK\$174 million, HK\$948 million, HK\$670 million and HK\$244 million respectively and the revenue of Central Wealth for the six months ended 30 June 2022 was approximately HK\$190 million. Whilst the revenues of Central Wealth would be affected a number of factors including the economic environment, it is noted that Central Wealth maintained annual revenues of not less than HK\$150 million in the past few years. The revenue of Central Wealth for the six months ended 30 June 2022 also indicates improvements in its performance in comparison with the year ended 31 December 2021.

The health awareness among people in the Mainland China is growing and the outbreak of COVID-19 further enhances people's awareness on the importance of health. Whilst Central Wealth had just commenced the traditional Chinese medicine business in February 2022 and had not generated any revenue from this business according to its interim report for the six months ended 30 June 2022, the Company considers that it would be in the interests of the Group to invest during the incubation stage instead at the mature stage. If Central Wealth can fully utilize the potentials of its traditional Chinese medicine business in the Mainland China, that would reflect in Central Wealth's performance and also its share price and that would in turn provide return to its shareholders.

In this regard, the Directors hold positive views towards the future prospects of Central Wealth.

By order of the Board
Future World Holdings Limited
Liang Jian
Chairman

Hong Kong, 2 December 2022

As at the date of this announcement, the Board comprises (i) eight executive Directors, namely Mr. Liang Jian, Mr. Yu Zhenzhong, Ms. Wang Qian, Mr. Yu Qingrui, Mr. Su Wei, Mr. Yuan Yifeng, Mr. Li Rui and Mr. Cheung Kit Shing; and (ii) three independent non-executive Directors, namely Mr. Chen Pei, Mr. He Yi and Mr. Guo Yaoli.